INTRODUCTION Contributed by: Lincoln Tsang, Ropes & Gray LLP
Navigating the Ever-Changing Global Regulatory Landscape: Adapting to Disruption and Uncertainty Welcome to the 2026 edition of Chambers & Part- ners’ Life Sciences Global Practice Guide. I would like to express my sincere gratitude to my colleagues for their expert contributions to this Guide. Their col- lective efforts have ensured comprehensive coverage of the latest developments across a wide range of regulatory, legal and policy issues in their respective jurisdictions. I would also like to take this opportunity to offer a few opening remarks. The global regulatory landscape for the life sciences sector is experiencing rapid and profound transforma- tion, shaped by policy innovation, regional divergence and mounting geopolitical pressures. As a result, organisations in this sector are encountering a more complex environment – one that presents both new opportunities and considerable uncertainties. Regulatory regimes around the world are evolving at an accelerated pace, with cross-border trends shaping innovation, compliance and enforcement. In 2026, we anticipate significant new developments that reflect the sector’s need to adapt to emerging scientific advances, shifting public health priorities and evolving political agendas. The interplay between regional regulatory approaches and the globalisation of life sciences innovation is intensifying the need for harmonisation, particularly in the design of clinical tri- als and the generation of evidence for rare diseases and digital health products. Leadership transitions at major regulatory agencies, especially in the United States, are influencing global priorities and creating a degree of uncertainty. Policy directions are shifting, with new initiatives focused on expedited approvals, increased transparency and alternative standards of evidence for products addressing unmet medical needs. These changes have direct implications for market access strategies, compliance expectations and enforcement risks. While the United States, European Union, United Kingdom and Asia are each pursuing distinct policy directions, there is a growing call for greater global collaboration and harmonisation. Divergent approach-
es to data exclusivity, market access and post-market surveillance are emerging, even as stakeholders seek to align on standards for innovative therapies and digi- tal health solutions. The need for harmonised regula- tory frameworks is particularly acute in areas such as rare diseases, where efficient evidence generation and timely patient access are critical. Regulators worldwide are placing greater emphasis on advertising, promotion and digital compliance, with stricter enforcement and higher expectations for organisational conduct becoming increasingly evi- dent. Developments such as enhanced transparency, real-time publication of regulatory decisions and more robust enforcement of direct-to-consumer advertising rules are reshaping the compliance landscape. In this context, life sciences companies are finding it neces- sary to adapt their approaches to enforcement risk and strengthen post-market oversight. Geopolitical tensions, trade investigations and shift- ing tariff threats are prompting a renewed emphasis on domestic production and localised supply mod- els. The United States and the European Union are prioritising domestic manufacturing, while China is advancing local supply chains to enhance resilience. These trends are influencing long-term investment planning, pricing strategies and the management of supply chain risks. Recent regional conflicts have further exacerbated these challenges, with direct consequences for the cost of goods and the stability of supply chains. Dis- ruptions to critical raw materials, increased trans- portation costs and heightened border controls have resulted in greater volatility and unpredictability in sourcing and distribution. Life sciences companies are experiencing increased costs for both inputs and finished products, as well as delays in manufactur- ing and delivery timelines. These pressures are com- pelling organisations to reassess their supply chain strategies, diversify sourcing, and invest in greater resilience to mitigate the impact of ongoing and future disruptions. Heightened geopolitical volatility is contributing to con- siderable uncertainty in global drug pricing. The risk of international price compression is rising, as countries
6 CHAMBERS.COM
Powered by FlippingBook